Palisade Bio, Inc. (PALI) vs X4 Pharmaceuticals, Inc. (XFOR)
A side-by-side comparison of Palisade Bio, Inc. and X4 Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PALI
Palisade Bio, Inc.
$1.50HealthcareDelayed quote: Oct 6, 2026, 1:40 PM EDT
XFOR
X4 Pharmaceuticals, Inc.
$2.76HealthcareDelayed quote: Oct 6, 2026, 1:35 PM EDT
Total return — PALI vs XFOR
growth of $100 · dividends reinvested · last 9yPALI -100.0% (-70.6%/yr)XFOR -99.9% (-52.9%/yr)XFOR compounded faster over this window
Log scale — wide-divergence pair
PALI XFOR
PALI vs XFOR: by the numbers
- •XFOR is the larger company ($260M vs $260M market cap).
- •Both run net losses; XFOR's is the smaller (-568.80% vs -6388.20% net margin).
Metrics side by side
Valuation
| Metric | PALI | XFOR |
|---|---|---|
| P/S ratio | 519.00 | 16.40 |
| P/B ratio | 2.13 | 1.67 |
Profitability
| Metric | PALI | XFOR |
|---|---|---|
| Gross margin | 0.00% | 81.22% |
| Operating margin | 0.00% | -247.44% |
| Net margin | -6388.20% | -568.80% |
| ROE | -26.24% | -57.98% |
| ROIC | -28.96% | -37.61% |
Growth (annualized)
| Metric | PALI | XFOR |
|---|---|---|
| Total return CAGR (5Y) | -76.02% | -55.06% |
Frequently asked
- How have PALI and XFOR total returns compared?
- Over the past 5 years, PALI delivered -76.02% and XFOR delivered -55.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.